ALX Oncology Inc. (ALXO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ALX Oncology Inc. (ALXO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.59

-0.10 (-5.92%)

At close: Jan 14, 2025, 3:59 PM

1.60

0.63%

Pre-market Jan 15, 2025, 05:32 AM EST

undefined% (undefined)

Bid	1.59
Market Cap	83.86M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.97
PE Ratio (ttm)	-0.54
Forward PE	n/a
Analyst	Buy

Ask	1.73
Volume	512,985
Avg. Volume (20D)	1,028,106
Open	1.69
Previous Close	1.69
Day's Range	1.59 - 1.77
52-Week Range	1.19 - 17.82
Beta	undefined

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell c...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 17, 2020

Employees 89

Stock Exchange NASDAQ

Ticker Symbol ALXO

Website https://www.alxoncology.com

Analyst Forecast

According to 6 analyst ratings, the average rating for ALXO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 151.57% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago · Source

-19.57%

ALX Oncology shares are trading lower after Jeffer... Unlock content with Pro Subscription

5 months ago · Source

-41.67%

ALX Oncology Holdings shares are trading lower. The company announced topline data from its ASPEN-06 Phase 2 trial.

News

1 week ago · zacks.com

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.

1 month ago · zacks.com

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin...